Vaxart, Inc.

NasdaqCM:VXRT 주식 보고서

시가총액: US$186.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Vaxart 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Steven Lo

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권n/a
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간3.1yrs

최근 관리 업데이트

Recent updates

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Vaxart: An Update

Oct 02

Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

Aug 25
Companies Like Vaxart (NASDAQ:VXRT) Are In A Position To Invest In Growth

CEO

Steven Lo (57 yo)

less than a year

테뉴어

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...


리더십 팀

이름위치테뉴어보상소유권
Sean Tucker
Senior VP & Chief Scientific Officer14.6yrsUS$1.14m0.10%
$ 194.5k
James Cummings
Chief Medical Officer3.1yrsUS$1.17m0.063%
$ 118.4k
Steven Lo
Presidentless than a year데이터 없음데이터 없음
Phillip Eric Lee
CFO, Principal Financial Officer & Principal Accounting Officer1.8yrs데이터 없음0.036%
$ 66.8k
Raymond Stapleton
Chief Technology Officer2.1yrs데이터 없음데이터 없음
Edward Berg
Senior VP & General Counsel2.6yrs데이터 없음0.050%
$ 92.9k
Shaily Garg
Senior Vice President of Clinical Development & Project Management4.5yrs데이터 없음데이터 없음
Rajesh Kapoor
Senior Vice President of Quality3.7yrs데이터 없음데이터 없음

2.8yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: VXRT 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Steven Lo
Presidentless than a year데이터 없음데이터 없음
Robert Yedid
Independent Director4.9yrsUS$92.26k0.0081%
$ 15.2k
Harry Greenberg
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음
Elaine Heron
Independent Director2.1yrsUS$89.08k0.011%
$ 20.2k
Michael Finney
Independent Chairman of the Board6.6yrsUS$109.57k0.29%
$ 550.8k
Stefan Gravenstein
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음
David Wheadon
Independent Director3.4yrsUS$93.72k0.0065%
$ 12.1k
Robert Belshe
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음
William Watson
Independent Director2.1yrsUS$94.76k0.023%
$ 42.9k
Marion Pepper
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음
Ralph Baric
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음
Gregory Gray
Member of Scientific & Clinical Advisory Board3.1yrs데이터 없음데이터 없음

3.1yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: VXRT 의 이사회경험(평균 재직 기간 3 년)으로 간주됩니다.